MyMD discusses Phase 2 results for MYMD-1 in sarcopenia/frailty; transcript furnished without specific data

Q/C TECHNOLOGIES, INC.

Conference call held August 2, 2023 to discuss Phase 2 results of oral TNF-α inhibitor MYMD-1.
Indication: chronic inflammation associated with sarcopenia (age-related frailty).
Transcript furnished as Exhibit 99.1 but appended text does not contain quantitative results.
Participants included Chairman Josh Silverman, President Chris Chapman, and CSO Adam Kaplin.
No safety or efficacy endpoints, trial sizes, or statistical outcomes disclosed in the provided exhibit excerpt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.